Table 1_Statin use during intensive care unit stay is associated with improved clinical outcomes in critically ill patients with sepsis: a cohort study.docx by Caifeng Li (3912883)

“…Additionally, statin use was associated with decreased ICU mortality (odds ratio [OR], 0.43; 95% CI, 0.37-0.49; p < 0.001) and reduced in-hospital mortality (OR, 0.50; 95% CI, 0.45-0.57; p < 0.001). …”

Table 3_Statin use during intensive care unit stay is associated with improved clinical outcomes in critically ill patients with sepsis: a cohort study.docx by Caifeng Li (3912883)

“…Additionally, statin use was associated with decreased ICU mortality (odds ratio [OR], 0.43; 95% CI, 0.37-0.49; p < 0.001) and reduced in-hospital mortality (OR, 0.50; 95% CI, 0.45-0.57; p < 0.001). …”

Table 4_Statin use during intensive care unit stay is associated with improved clinical outcomes in critically ill patients with sepsis: a cohort study.pdf by Caifeng Li (3912883)

“…Additionally, statin use was associated with decreased ICU mortality (odds ratio [OR], 0.43; 95% CI, 0.37-0.49; p < 0.001) and reduced in-hospital mortality (OR, 0.50; 95% CI, 0.45-0.57; p < 0.001). …”

Table 2_Statin use during intensive care unit stay is associated with improved clinical outcomes in critically ill patients with sepsis: a cohort study.docx by Caifeng Li (3912883)

“…Additionally, statin use was associated with decreased ICU mortality (odds ratio [OR], 0.43; 95% CI, 0.37-0.49; p < 0.001) and reduced in-hospital mortality (OR, 0.50; 95% CI, 0.45-0.57; p < 0.001). …”

Image 2_Statin use during intensive care unit stay is associated with improved clinical outcomes in critically ill patients with sepsis: a cohort study.jpeg by Caifeng Li (3912883)

“…Additionally, statin use was associated with decreased ICU mortality (odds ratio [OR], 0.43; 95% CI, 0.37-0.49; p < 0.001) and reduced in-hospital mortality (OR, 0.50; 95% CI, 0.45-0.57; p < 0.001). …”

Image 3_Statin use during intensive care unit stay is associated with improved clinical outcomes in critically ill patients with sepsis: a cohort study.jpeg by Caifeng Li (3912883)

“…Additionally, statin use was associated with decreased ICU mortality (odds ratio [OR], 0.43; 95% CI, 0.37-0.49; p < 0.001) and reduced in-hospital mortality (OR, 0.50; 95% CI, 0.45-0.57; p < 0.001). …”

Image 1_Statin use during intensive care unit stay is associated with improved clinical outcomes in critically ill patients with sepsis: a cohort study.jpeg by Caifeng Li (3912883)

“…Additionally, statin use was associated with decreased ICU mortality (odds ratio [OR], 0.43; 95% CI, 0.37-0.49; p < 0.001) and reduced in-hospital mortality (OR, 0.50; 95% CI, 0.45-0.57; p < 0.001). …”

Image 3_Vitamin D supplementation during intensive care unit stay is associated with improved outcomes in critically Ill patients with sepsis: a cohort study.jpeg by Caifeng Li (3912883)

“…</p>Methods<p>We conducted a retrospective cohort study using data from MIMIC-IV database, a publicly available database containing clinical information on patients admitted to the ICU at Beth Israel Deaconess Medical Center (BIDMC) from 2008 to 2019. …”

Image 4_Vitamin D supplementation during intensive care unit stay is associated with improved outcomes in critically Ill patients with sepsis: a cohort study.jpeg by Caifeng Li (3912883)

“…</p>Methods<p>We conducted a retrospective cohort study using data from MIMIC-IV database, a publicly available database containing clinical information on patients admitted to the ICU at Beth Israel Deaconess Medical Center (BIDMC) from 2008 to 2019. …”

Table 1_Vitamin D supplementation during intensive care unit stay is associated with improved outcomes in critically Ill patients with sepsis: a cohort study.docx by Caifeng Li (3912883)

“…</p>Methods<p>We conducted a retrospective cohort study using data from MIMIC-IV database, a publicly available database containing clinical information on patients admitted to the ICU at Beth Israel Deaconess Medical Center (BIDMC) from 2008 to 2019. …”

Image 1_Vitamin D supplementation during intensive care unit stay is associated with improved outcomes in critically Ill patients with sepsis: a cohort study.jpeg by Caifeng Li (3912883)

“…</p>Methods<p>We conducted a retrospective cohort study using data from MIMIC-IV database, a publicly available database containing clinical information on patients admitted to the ICU at Beth Israel Deaconess Medical Center (BIDMC) from 2008 to 2019. …”

Table 3_Vitamin D supplementation during intensive care unit stay is associated with improved outcomes in critically Ill patients with sepsis: a cohort study.docx by Caifeng Li (3912883)

“…</p>Methods<p>We conducted a retrospective cohort study using data from MIMIC-IV database, a publicly available database containing clinical information on patients admitted to the ICU at Beth Israel Deaconess Medical Center (BIDMC) from 2008 to 2019. …”

Table 2_Vitamin D supplementation during intensive care unit stay is associated with improved outcomes in critically Ill patients with sepsis: a cohort study.docx by Caifeng Li (3912883)

“…</p>Methods<p>We conducted a retrospective cohort study using data from MIMIC-IV database, a publicly available database containing clinical information on patients admitted to the ICU at Beth Israel Deaconess Medical Center (BIDMC) from 2008 to 2019. …”

Image 2_Vitamin D supplementation during intensive care unit stay is associated with improved outcomes in critically Ill patients with sepsis: a cohort study.jpeg by Caifeng Li (3912883)

“…</p>Methods<p>We conducted a retrospective cohort study using data from MIMIC-IV database, a publicly available database containing clinical information on patients admitted to the ICU at Beth Israel Deaconess Medical Center (BIDMC) from 2008 to 2019. …”

Table_1_v1_Role of Female Research at the Asociacion Mexicana de Cirugia General Annual Meeting: A Retrospective Analysis From 2013 to 2019.docx by Lorelí Mejía-Fernández (12539746)

“…Females’ abstracts submitted have a 50 23.5% decreased chance of being selected for oral presentation (OR = 0.765, CI 95%, 0.639–0.917, 51 p = 0.003). …”

Table_1_v1_Role of Female Research at the Asociacion Mexicana de Cirugia General Annual Meeting: A Retrospective Analysis From 2013 to 2019.docx by Lorelí Mejía-Fernández (12539746)

“…Females’ abstracts submitted have a 50 23.5% decreased chance of being selected for oral presentation (OR = 0.765, CI 95%, 0.639–0.917, 51 p = 0.003). …”

Table 1_Global burden of childhood otitis media attributable to secondhand smoke from 1990 to 2021: a systematic analysis of the global burden of disease study 2021.docx by Bei Li (90587)

“…</p>Conclusion<p>While there has been a general decrease in the global burden of childhood otitis media linked to secondhand smoke exposure. …”

Data Sheet 2_Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus.docx by Haoyi Yang (8215116)

“…</p>Study design<p>In the phase Ib study, a total of 50 participants with T2DM were enrolled and randomly assigned to the 0.5 mg BID, 1 mg BID, 2 mg BID, 1 mg QD, and 2 mg QD dose groups, with a 4:1 random allocation within each group to receive either the SY-009 capsule or placebo. …”

DataSheet_1_Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study.docx by Daidi Zhao (5179145)

“…</p>Results<p>Of 108 patients, 80 (74.1%) initiated low-dose RTX therapy immediately after acute attack treatment and 33 (30.6%) initiated it after the first attack. During a median treatment period of 35.5 (22.0–48.8) months, significant decreases were observed in median ARR (1.1 [0.8–2.0] versus 0 [0–0.2], p < 0.001), EDSS score (3.5 [2.5–4.0] versus 2.0 [1.0–3.0], p < 0.001) and spinal cord lesion segments (5.0 [4.0–8.0] versus 3.0 [1.0–6.0], p < 0.001). …”

Data Sheet 1_Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus.docx by Haoyi Yang (8215116)

“…</p>Study design<p>In the phase Ib study, a total of 50 participants with T2DM were enrolled and randomly assigned to the 0.5 mg BID, 1 mg BID, 2 mg BID, 1 mg QD, and 2 mg QD dose groups, with a 4:1 random allocation within each group to receive either the SY-009 capsule or placebo. …”